{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:40:13Z","timestamp":1789594813663,"version":"build-2803163510"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.rdc.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T08:12:50Z","timestamp":1681805570000},"page":"505-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Giant Cell Arteritis and Polymyalgia Rheumatica"],"prefix":"10.1016","volume":"49","author":[{"given":"Desh","family":"Nepal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Putman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Unizony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.rdc.2023.03.005_bib1","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"22","key":"10.1016\/j.rdc.2023.03.005_bib3","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.005_bib4","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"9860","key":"10.1016\/j.rdc.2023.03.005_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(12)60680-1","article-title":"Polymyalgia rheumatica","volume":"381","author":"Kermani","year":"2013","journal-title":"Lancet"},{"issue":"9634","key":"10.1016\/j.rdc.2023.03.005_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1056\/NEJMcp1214825","article-title":"Clinical practice. Giant-cell arteritis and polymyalgia rheumatica","volume":"371","author":"Weyand","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.005_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra022694","article-title":"Medium- and large-vessel vasculitis","volume":"349","author":"Weyand","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2021-220955","article-title":"Novel aspects of regulatory T\u00a0cell dysfunction as a therapeutic target in giant cell arteritis","volume":"81","author":"Adriawan","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.005_bib10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2016-210070","article-title":"An expanded population of pathogenic regulatory T\u00a0cells in giant cell arteritis is abrogated by IL-6 blockade therapy","volume":"76","author":"Miyabe","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.005_bib11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.autrev.2017.05.014","article-title":"Recent advances in our understanding of giant cell arteritis pathogenesis","volume":"16","author":"Samson","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rdc.2023.03.005_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/scitranslmed.aal3322","article-title":"The microvascular niche instructs T\u00a0cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway","volume":"9","author":"Wen","year":"2017","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.rdc.2023.03.005_bib13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","article-title":"Immune mechanisms in medium and large-vessel vasculitis","volume":"9","author":"Weyand","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2023.03.005_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2019.02.007","article-title":"Cytokines, growth factors and proteases in medium and large vessel vasculitis","volume":"206","author":"Weyand","year":"2019","journal-title":"Clin Immunol"},{"issue":"11","key":"10.1016\/j.rdc.2023.03.005_bib15","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.005_bib16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-cell responses in giant cell arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.005_bib17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.005_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","article-title":"Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study","volume":"55","author":"Labarca","year":"2016","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.005_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.semarthrit.2020.04.004","article-title":"Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study","volume":"50","author":"Muratore","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.005_bib20","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","article-title":"Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment","volume":"41","author":"Gonzalez-Gay","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.005_bib21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0161-6420(03)00228-8","article-title":"Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy","volume":"110","author":"Hayreh","year":"2003","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.rdc.2023.03.005_bib22","doi-asserted-by":"crossref","first-page":"e3210","DOI":"10.1097\/MD.0000000000003210","article-title":"Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study","volume":"95","author":"Hocevar","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.005_bib23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/acr.24632","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018\u00a0Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.005_bib25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"20","key":"10.1016\/j.rdc.2023.03.005_bib26","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/archinternmed.2009.352","article-title":"Treatment of polymyalgia rheumatica: a systematic review","volume":"169","author":"Hernandez-Rodriguez","year":"2009","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.005_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","article-title":"An initially double-blind controlled 96\u00a0week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica","volume":"37","author":"Dasgupta","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2474-12-94","article-title":"The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity","volume":"12","author":"Cimmino","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.005_bib29","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.005_bib30","doi-asserted-by":"crossref","first-page":"ITC65","DOI":"10.7326\/AITC201705020","article-title":"Polymyalgia Rheumatica","volume":"166","author":"Matteson","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.005_bib31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.03.005_bib32","doi-asserted-by":"crossref","first-page":"152010","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.005_bib33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.005_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13075-019-1837-7","article-title":"Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.005_bib36","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rheumatology"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.005_bib37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","article-title":"Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis","volume":"57","author":"Reichenbach","year":"2018","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13075-020-02377-8","article-title":"Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations","volume":"23","author":"Unizony","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.rdc.2023.03.005_bib39","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2021-220347","article-title":"Treatment failure in giant cell arteritis","volume":"80","author":"Unizony","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.005_bib40","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2023.03.005_bib41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2022-eular.5004a","article-title":"LB0006 sarilumab in patients with relapsing polymyalgia rheumatica: a phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR)","volume":"81","author":"Dasgupta","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.005_bib42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.005_bib43","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.005_bib44","first-page":"495","article-title":"A\u00a0prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.005_bib45","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.005_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.005_bib47","first-page":"1550","article-title":"The use of methotrexate in polymyalgia rheumatica","volume":"23","author":"Feinberg","year":"1996","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.005_bib48","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.005_bib49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.005_bib50","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.23901","article-title":"Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis","volume":"72","author":"Mainbourg","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib51","doi-asserted-by":"crossref","first-page":"102930","DOI":"10.1016\/j.autrev.2021.102930","article-title":"Epidemiology of major relapse in giant cell arteritis: A study-level meta-analysis","volume":"21","author":"Aussedat","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.005_bib52","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A\u00a0Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 129","key":"10.1016\/j.rdc.2023.03.005_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.55563\/clinexprheumatol\/l0hd9v","article-title":"An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis","volume":"39","author":"Rossi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.005_bib54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.005_bib55","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the Treatment of Giant Cell Arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib56","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s13063-021-05520-1","article-title":"Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial","volume":"22","author":"Venhoff","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.rdc.2023.03.005_bib57","article-title":"Secukinumab in giant cell arteritis: a randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 2 trial Arthritis","volume":"73","author":"Venhoff","year":"2021","journal-title":"Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.005_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","article-title":"Targeting GM-CSF in inflammatory diseases","volume":"12","author":"Wicks","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.005_bib59","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/annrheumdis-2021-220873","article-title":"Blocking GM-CSF receptor alpha with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex\u00a0vivo cultured arteries from patients with giant cell arteritis","volume":"81","author":"Corbera-Bellalta","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.005_bib60","doi-asserted-by":"crossref","first-page":"e1164","DOI":"10.1002\/cti2.1164","article-title":"Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis","volume":"9","author":"Jiemy","year":"2020","journal-title":"Clin Transl Immunology"},{"issue":"12","key":"10.1016\/j.rdc.2023.03.005_bib61","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/art.41887","article-title":"A\u00a0Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL-40\/Interleukin-13 Receptor alpha2 Axis","volume":"73","author":"van Sleen","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2023.03.005_bib62","article-title":"GM-CSF is a pro-inflammatory cytokine in experimental vasculitis of medium and large arteries [abstract 1766]","volume":"71","author":"Watanabe","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2023.03.005_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2023.03.005_bib64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41927-017-0004-5","article-title":"Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets","volume":"1","author":"Koster","year":"2017","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.rdc.2023.03.005_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","author":"Koster","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.005_bib66","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.005_bib67","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/art.38625","article-title":"Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica","volume":"66","author":"van der Geest","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.005_bib68","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0000000000000265","article-title":"Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis","volume":"28","author":"Koster","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.005_bib69","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B\u00a0cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J\u00a0Exp Med"},{"issue":"11","key":"10.1016\/j.rdc.2023.03.005_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of Rituximab in Patients with Polymyalgia Rheumatica: A Double-Blind, Randomised, Placebo-Controlled, Proof-of-Concept Trial The","volume":"3","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.005_bib71","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1136\/annrheumdis-2016-210792","article-title":"Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis","volume":"76","author":"Planas-Rigol","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.005_bib72","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ard.2008.105692","article-title":"Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events","volume":"69","author":"Lozano","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.005_bib73","doi-asserted-by":"crossref","first-page":"E619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm open-label, proof-of-concept study","volume":"3","author":"Christ","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.rdc.2023.03.005_bib74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2022-eular.2096","article-title":"Tocilizumab in combination with 8 weeks of prednisone for giant cell arteritis","volume":"81","author":"Unizony","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.005_bib75","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.005_bib76","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40744-020-00227-2","article-title":"A\u00a0Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis","volume":"7","author":"Schmidt","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"12","key":"10.1016\/j.rdc.2023.03.005_bib77","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.005_bib78","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A\u00a0double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.005_bib79","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:31:23Z","timestamp":1760182283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X23000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0889857X23000364"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2023.03.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Giant Cell Arteritis and Polymyalgia Rheumatica","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}